Xtl Biopharmaceuticals Ltd Stock Performance
| XTLB Stock | USD 2.10 0.22 11.70% |
The firm maintains a market beta of 1.2, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, XTL Biopharmaceutica will likely underperform. XTL Biopharmaceuticals presently maintains a risk of 7.83%. Please check out XTL Biopharmaceuticals semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if XTL Biopharmaceuticals will be following its historical returns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days XTL Biopharmaceuticals Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong essential indicators, XTL Biopharmaceutica is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 19.32 | Five Day Return 44.83 | Year To Date Return 114.86 | Ten Year Return (80.28) | All Time Return (99.63) |
Last Split Factor 1:5 | Dividend Date 2017-02-10 | Last Split Date 2017-02-10 |
1 | Provectus Biopharmaceuticals GAAP EPS of 0.00, revenue of 0.11M | 11/14/2024 |
2 | SK Biopharmaceuticals Co., Ltd. Shares Could Be 47 percent Below Their Intrinsic Value Estimate | 11/27/2024 |
3 | Atlas Venture Announces 450 Million Fund XIV | 12/05/2024 |
4 | Meitheal Pharmaceuticals Grows Specialty Biopharmaceuticals Portfolio with Exclusive Commercial Licensing Agreement for XENLETA | 12/11/2024 |
5 | HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager To Treat Solid Tumor Cancers | 12/17/2024 |
6 | TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke and TTP | 12/19/2024 |
7 | Acquisition by Edelman Joseph of 32260 shares of XTL Biopharmaceutica at 3.36 subject to Rule 16b-3 | 12/24/2024 |
| Begin Period Cash Flow | 2.1 M |
XTL |
XTL Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 240.00 in XTL Biopharmaceuticals Ltd on September 28, 2024 and sell it today you would lose (30.00) from holding XTL Biopharmaceuticals Ltd or give up 12.5% of portfolio value over 90 days. XTL Biopharmaceuticals Ltd is currently generating 0.0822% in daily expected returns and assumes 7.8315% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than XTL, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
XTL Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XTL Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XTL Biopharmaceuticals Ltd, and traders can use it to determine the average amount a XTL Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0105
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | XTLB |
| Negative Returns |
Estimated Market Risk
| 7.83 actual daily | 69 69% of assets are less volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average XTL Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XTL Biopharmaceutica by adding XTL Biopharmaceutica to a well-diversified portfolio.
XTL Biopharmaceutica Fundamentals Growth
XTL Stock prices reflect investors' perceptions of the future prospects and financial health of XTL Biopharmaceutica, and XTL Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XTL Stock performance.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 5.45 M | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 3.79 X | ||||
| EBITDA | (764 K) | ||||
| Net Income | (1.78 M) | ||||
| Cash And Equivalents | 5.16 M | ||||
| Cash Per Share | 0.95 X | ||||
| Total Debt | 206 K | ||||
| Current Ratio | 31.26 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (707 K) | ||||
| Earnings Per Share | (0.03) X | ||||
| Market Capitalization | 10.24 M | ||||
| Total Asset | 2.43 M | ||||
| Retained Earnings | (158.25 M) | ||||
| Working Capital | 1.84 M | ||||
| Current Asset | 3 M | ||||
About XTL Biopharmaceutica Performance
By analyzing XTL Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into XTL Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if XTL Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if XTL Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 17.2 M | 18.1 M | |
| Return On Capital Employed | (0.34) | (0.33) |
Things to note about XTL Biopharmaceuticals performance evaluation
Checking the ongoing alerts about XTL Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XTL Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XTL Biopharmaceutica had very high historical volatility over the last 90 days | |
| XTL Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (707 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95. | |
| XTL Biopharmaceutica has a frail financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke and TTP |
- Analyzing XTL Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XTL Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining XTL Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XTL Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XTL Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XTL Biopharmaceutica's stock. These opinions can provide insight into XTL Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |